Clinical briefs from Novartis, Gilead and AstraZeneca The Pharma Letter The trial evaluated the introduction of Certican (everolimus) with reduced exposure tacrolimus administered twice-daily starting one month after liver transplantation versus standard-exposure tacrolimus. In October, European health authorities approved ... |
